[Response of growth hormone to the acute test using GH-releasing factor 1-29 in acromegaly. Comparison in the baseline situation and under treatment with prolonged-action somatostatin].

Plain Language Summary

This study evaluated the growth hormone response to sermorelin in patients with acromegaly, comparing results at baseline and during treatment with a long-acting somatostatin analog. The findings help clarify how pituitary tumors respond to growth hormone-releasing hormone stimulation and how somatostatin therapy modifies that response.